Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | NOS1 | P29475 | 4/20 | 0.39 |
| ▸ | NOS2 | P35228 | 4/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.37 |
| ▸ | CTRC | Q99895 | 2/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 2/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3637263 | 0.90 | NOS1 (0.46) | FAAHNOS1NOS2PRSS1CTRC | |
| SCHEMBL10431414 | 0.84 | FAAH (0.35) | FAAHNOS1NOS2PRSS1CTRC | |
| SCHEMBL17964253 | 0.84 | TP53 (0.49) | FAAHNOS1NOS2PRSS1CTRC | |
| SCHEMBL6429233 | 0.78 | ALDH1A1 (0.38) | FAAHNOS1NOS2PRSS1CTRC | |
| SCHEMBL17964264 | 0.77 | TP53 (0.50) | FAAHNOS1NOS2PRSS1CTRC | |
| SCHEMBL3535755 | 0.77 | NOS1 (0.40) | FAAHNOS1NOS2PRSS1CTRC | |
| SCHEMBL3259636 | 0.75 | — | — | |
| SCHEMBL19302160 | 0.75 | — | — | |
| SCHEMBL29554100 | 0.75 | — | — | |
| SCHEMBL17964290 | 0.75 | FAAH (0.33) | FAAHTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6043270-A | ANTIINFLAMMATORY AGENTS | PROCYON PHARMACEUTICALS, INC. (US) | 2000-03-28 | — | — | US | claimed |
| US-20050054662-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB (SE) | 2005-03-10 | — | — | US | disclosed |
| US-20050009928-A1 | Cyclopentanone derivative | ZEON CORPORATION (JP) | 2005-01-13 | — | — | US | disclosed |
| EP-1420005-A1 | CYCLOPENTANONE DERIVATIVE | Zeon Corporation (JP) | 2004-05-19 | — | — | EP | disclosed |
| EP-1084096-B1 | METHOD FOR PRODUCING CYCLOPENTANONE | BASF AG (DE) | 2003-10-01 | — | — | EP | disclosed |
| US-6429339-B1 | CYCLIZATION OF ADIPIC DIESTER USING ALKALI, ALKALINE EARTH OR RARE EARTH METAL OXIDE OXIDIC CATALYST; TITANIA, ZIRCONIA OR ZINC OXIDE CATALYST SUPPORTS | BASF AKTIENGESELLSCHAFT (DE) | 2002-08-06 | — | — | US | disclosed |
| EP-1084096-A1 | METHOD FOR PRODUCING CYCLOPENTANONE | BASF AKTIENGESELLSCHAFT (DE) | 2001-03-21 | — | — | EP | disclosed |
| WO-1999061402-A1 | METHOD FOR PRODUCING CYCLOPENTANONE | BASF AKTIENGESELLSCHAFT (DE) | 1999-12-02 | — | — | WO | disclosed |
| EP-0398099-B1 | PROCESS FOR THE PRODUCTION OF CYCLOPENTANONES | BASF Aktiengesellschaft (DE) | 1993-09-22 | — | — | EP | disclosed |
| US-5166447-A | Preparation of cyclopentanones | BASF AKTIENGESELLSCHAFT (DE) | 1992-11-24 | — | — | US | disclosed |
| US-5081309-A | PREPARATION OF 2-ALKYLCYCLOPENTANONES | BASF AKTIENGESELLSCHAFT (DE) | 1992-01-14 | — | — | US | disclosed |
| EP-0398099-A1 | Process for the production of cyclopentanones | BASF Aktiengesellschaft (DE) | 1990-11-22 | — | — | EP | disclosed |
| EP-0194591-B1 | PROCESS FOR THE PREPARATION OF 2-ALKYL-CYCLOPENTANONES | BASF Aktiengesellschaft (DE) | 1988-08-24 | — | — | EP | disclosed |
| EP-0194591-A2 | Process for the preparation of 2-alkyl-cyclopentanones | BASF Aktiengesellschaft (DE) | 1986-09-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009928-A1 | Cyclopentanone derivative | PTGIS, CYP51A1, TRPA1 | FAAH 99/4885NOS1 84/4885NOS2 103/4885 |
| US-20050054662-A1 | Quinazoline derivatives as antitumor agents | ERBB2, ERBB3, ABL1 | FAAH 4649/4885NOS1 1543/4885NOS2 1348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.